JPMorgan analyst Jessica Fye after the close last night upgraded BioCryst Pharmaceuticals to Overweight from Neutral and raised her price target for the shares to $9 from $6. The shares closed yesterday down 7c to $4.93. The analyst views the company's final results from the APeX-1 trial for BCX7353 in the prevention of hereditary angioedema attacks as encouraging. The results confirm an effective HAE attack prevention agent and one that justifies a valuation greater than the company's current $400M market capitalization, Fye tells investors in a research note.